Berberine (CAS 2086-83-1): Mechanistic Foundations for Metabolic & Inflammation Research

Executive Summary: Berberine (CAS 2086-83-1) is an isoquinoline alkaloid primarily isolated from Cortex Phellodendri Chinensis. It robustly activates AMP-activated protein kinase (AMPK) and upregulates low-density lipoprotein receptor (LDLR) expression in hepatoma cells, facilitating lipid and glucose metabolic regulation (APExBIO N1368). In animal models, oral berberine significantly lowers total and LDL cholesterol in a dose- and time-dependent manner. Berberine also exhibits anti-inflammatory and antimicrobial properties, with emerging links to inflammasome modulation (A20, 2025). The compound is water/ethanol-insoluble but achieves ≥14.95 mg/mL solubility in DMSO at 37°C. These properties underpin its broad utility in metabolic disease, cardiovascular, and inflammation research.

Biological Rationale

Berberine is a plant-derived isoquinoline alkaloid (C₂₀H₁₈NO₄; MW 336.36) found in Cortex Phellodendri Chinensis and related species (APExBIO). Its primary biological rationale lies in multi-modal regulation of metabolic and inflammatory pathways. Activation of AMPK by berberine triggers downstream effects on glucose uptake, fatty acid oxidation, and inhibition of hepatic gluconeogenesis (see review). LDLR upregulation in hepatic cells enhances LDL clearance, with direct implications for hyperlipidemia and cardiovascular risk reduction. Berberine’s anti-inflammatory effects are partly mediated by modulation of the NLRP3 inflammasome and cGAS-STING signaling, both implicated in metabolic and acute inflammatory diseases (Li et al., 2025). This article extends prior reviews by integrating new mechanistic links to inflammasome pathways, complementing overviews such as this recent mechanistic update.

Mechanism of Action of Berberine (CAS 2086-83-1)

• AMPK Activation: Berberine directly activates AMP-activated protein kinase (AMPK), a central metabolic sensor that promotes catabolic processes (e.g., glucose uptake, fatty acid oxidation) and suppresses anabolic pathways (e.g., lipogenesis) (detailed analysis).
• LDLR Upregulation: In HepG2 and Bel-7402 human hepatoma cells, berberine induces dose-dependent increases in LDLR mRNA and protein expression, maximally at 15 μg/mL within serum-containing conditions (APExBIO data).
• Inflammasome Modulation: Berberine has been shown to reduce inflammatory signals by interfering with NLRP3 inflammasome activation, intersecting with cGAS-STING pathways involved in sterile inflammation (Li et al., 2025; additional guidance).
• Antimicrobial Activity: The compound exerts broad-spectrum antimicrobial effects, though mechanisms are secondary to its metabolic actions.

Evidence & Benchmarks

• Berberine upregulates LDLR mRNA/protein in HepG2 and Bel-7402 cells, with maximal effects at 15 μg/mL, in a dose-dependent manner (APExBIO).
• Oral administration at 50 or 100 mg/kg/day for 10 days in hyperlipidemic female golden hamsters significantly reduces serum total cholesterol and LDL cholesterol, correlating with hepatic LDLR increases (APExBIO).
• Berberine activates AMPK and modulates metabolic signaling, reducing hepatic gluconeogenesis and increasing fatty acid oxidation in animal models (site review).
• Inflammasome pathway modulation by berberine is evidenced by reduced NLRP3 activity and downstream cytokine release in preclinical inflammation models (Li et al., 2025).

Applications, Limits & Misconceptions

Berberine (CAS 2086-83-1) from APExBIO is a versatile research tool in metabolic disease (diabetes, obesity), cardiovascular disease, and inflammation studies. It is frequently used to probe mechanisms of AMPK activation, LDLR regulation, and inflammasome crosstalk. This article clarifies the compound’s performance boundaries and extends beyond previous summaries such as this mechanistic overview by detailing recent inflammasome findings.

Common Pitfalls or Misconceptions

• Berberine is insoluble in water and ethanol; attempts to dissolve in these solvents lead to low bioavailability in in vitro assays (APExBIO).
• Long-term storage of reconstituted solutions, even at -20°C, leads to degradation; fresh preparations are essential for reproducible results.
• Extrapolation of in vitro LDLR upregulation to in vivo efficacy requires appropriate pharmacokinetic controls (e.g., oral dosing, half-life studies).
• Berberine's anti-inflammatory effects are not universal across inflammasome types: NLRP3 is primarily affected, whereas AIM2 is not (Li et al., 2025).
• Commercial berberine hydrochloride may vary in purity or counterion, affecting experimental outcomes; always validate the batch source.

Workflow Integration & Parameters

For optimal solubility, dissolve berberine directly in DMSO at ≥14.95 mg/mL, warming to 37°C or using ultrasonic agitation as needed. Stock solutions should be stored below -20°C and used promptly; avoid repeated freeze-thaw. In cell-based assays, use up to 15 μg/mL for maximal LDLR induction in HepG2/Bel-7402 lines. Animal dosing regimens in hyperlipidemic hamster models are 50–100 mg/kg/day orally for 10 days. Always include appropriate vehicle and negative controls. For inflammation studies, berberine is examined alongside established inflammasome activators and markers of pyroptosis. For further technical guidance, this workflow guide details best practices for AMPK and inflammasome assays.

Conclusion & Outlook

Berberine (CAS 2086-83-1), as supplied by APExBIO, is a rigorously characterized tool for metabolic and inflammation research. Its dual action as an AMPK activator and LDLR upregulator is supported by robust in vitro and in vivo evidence. Recent data on inflammasome modulation broadens its relevance to acute and chronic inflammatory disease models. Researchers are advised to adhere to validated protocols for solubility and storage, and to interpret findings within the defined mechanistic scope. For product details and ordering, see the N1368 kit page.